NCT05015764

Reprieve Cardiovascular System for the Treatment of Subjects With Acute Decompensated Heart Failure Mechanistic Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Reprieve Cardiovascular, Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Reprieve Cardiovascular System for the Treatment of Subjects with Acute Decompensated Heart Failure Mechanistic Study

Detailed description

The key objective of the trial was to provide an optimized decongestion treatment for subjects with acute decompensated heart failure and identify the critical parameters that could be incorporated into the design of the next generation of the Reprieve Cardiovascular System.

Conditions

• Heart Failure

Interventions

Type	Name	Description
OTHER	Fluid Management	Removal of excess extracellular fluid using diuretics
DEVICE	Reprieve Cardiovascular System	System with Fluid Management Module

Timeline

• Start date: 2021-04-12
• Primary completion: 2022-05-02
• Completion: 2022-05-02
• First posted: 2021-08-20
• Last updated: 2025-04-04

Locations

1 site across 1 country: Georgia

Regulatory

• FDA-regulated device study